thiophenes has been researched along with Hormone-Dependent Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gutgesell, LM; Karumudi, B; Lee, S; Lu, Y; Thatcher, GR; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J | 1 |
| Alho-Richmond, S; Huhtinen, K; Johansson, N; Karkola, S; Koskimies, P; Lilienkampf, A; Vihko, K; Wähälä, K | 1 |
| Chu, IM; Csiszar, K; Flanders, K; Green, JE; Hoenerhoff, M; Luger, D; Michalowski, AM; Oshima, A; Sato, M; Szauter, KM | 1 |
| Licun, W; Tannock, IF | 1 |
| Fabian, CJ; Kimler, BF | 1 |
| Katzenellenbogen, BS; Keith, D; Read, LD; Slamon, DJ | 1 |
1 review(s) available for thiophenes and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms | 2001 |
5 other study(ies) available for thiophenes and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Models, Molecular; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes | 2017 |
Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Line, Tumor; Estradiol Dehydrogenases; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Isoenzymes; Models, Molecular; Neoplasms, Hormone-Dependent; Pyrimidinones; Recombinant Proteins; Structure-Activity Relationship; Thiophenes | 2009 |
GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; GATA3 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Neoplasms, Basal Cell; Neoplasms, Hormone-Dependent; Prognosis; Protein-Lysine 6-Oxidase; Pyrimidines; Thiophenes | 2012 |
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Methotrexate; Neoplasms, Hormone-Dependent; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Humans; Mifepristone; Neoplasms, Hormone-Dependent; Progestins; Prognosis; Promegestone; Proto-Oncogene Proteins; Pyrrolidines; Receptor, ErbB-2; RNA, Messenger; RNA, Neoplasm; Thiophenes; Tumor Cells, Cultured | 1990 |